What the FDA labels say about taking them together
Glucagon and insulin glulisine
Insulin glulisine's FDA label of November 25, 2025 names glucagon in its drug interactions section; glucagon's label does not name insulin glulisine itself but warns about its class (insulin analogs). The insulin glulisine label: “Drugs that May Decrease the Blood Glucose Lowering Effect of APIDRA Drugs: Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, phenothiazine derivatives, progestogens …”
Check it at the source: the glucagon FDA label on DailyMed (effective August 11, 2026, Amphastar Pharmaceuticals, Inc.); the insulin glulisine FDA label on DailyMed (effective November 25, 2025).
What does the glucagon label say about insulin glulisine?
Glucagon's label does not name insulin glulisine itself; it warns about its class (insulin analogs):
Glucagon label, drug interactionsMonitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin.
Glucagon label, warnings and precautionsIn patients with insulinoma, glucagon administration may produce an initial increase in blood glucose; however, Glucagon for Injection may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia.
Source: FDA drug label (Glucagon), Amphastar Pharmaceuticals, Inc., effective August 11, 2026 (SPL set 8cc40354-b5ac-45b6-a211-93b44444f2a3), via openFDA; the full label on DailyMed
What does the insulin glulisine label say about glucagon?
Insulin glulisine label, drug interactionsDrugs that May Decrease the Blood Glucose Lowering Effect of APIDRA Drugs: Atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, phenothiazine derivatives, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when APIDRA is coadministered with these drugs.
Source: FDA drug label (Apidra), sanofi-aventis U.S. LLC, effective November 25, 2025 (SPL set e7af6a7a-8046-4fb4-9979-4ec4230b23aa), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glucagon | Insulin glulisine | |
|---|---|---|
| Labeled for | n/a | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $154.20 per kit 1 mg emergency kit | $8.16 per mL 100 unit/mL vial |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once